Technology area: Biotechnology & Pharmaceuticals
115 pending office actions • 68 art units • 106 examiners • 0 of 115 (0%) have an AI response strategy ready • 140 patents granted in the last 365 days
University of Florida Research Foundation Inc. has 120 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 110 distinct examiners and 69 distinct art units, indicating a broad examination footprint across many technical and administrative channels.
ROBINSON, HOPE A is the busiest examiner, with 3 pending matters. That assignment represents only a limited part of the portfolio workload, so centralized docket control and consistent response practices are important. Counsel should preserve matter-level ownership while using the art-unit distribution to identify recurring examination themes.
Based on the USPTO statutory response window for each pending office action. 29 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 29 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 13 (11%) |
| §103 only | 24 (21%) |
| §102 only | 4 (3%) |
| §112 only | 11 (10%) |
| Double-patenting + other | 14 (12%) |
| Multi-statute (no §101) | 45 (39%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 3 | 67.7% | +43.0% |
| JOHNSON, EMILY KATHARINE | 2 | 87.5% | +21.9% |
| CORNET, JEAN P | 2 | 41.9% | +47.2% |
| LIPPOLIS, ALEXANDRA ROSE | 2 | 47.2% | +63.6% |
| KONOPKA, CATHERINE ANNE | 2 | 57.5% | +66.2% |
| KASAYAN, KATRIEL BARCELLANO | 2 | 25.0% | +0.0% |
| PENNINGTON, KATIE LEIGH | 2 | 31.8% | +58.8% |
| WANG, CHANG YU | 2 | 33.4% | +53.7% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| MILO, MICHAEL | 1 | 50.8% | +52.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552486 | PREDICTION OF POST-OPERATIVE PAIN USING HOSVD | STONE, RACHAEL SOJIN | 77d overdue |
| 17772266 | GENE THERAPY VECTORS | PENNINGTON, KATIE LEIGH | 51d overdue |
| 18316064 | DISTRIBUTED LEDGER PLATFORM FOR ELECTRONIC VOTING AND/OR POLLING | LEE, CLAY C | 35d overdue |
| 17802872 | COMPOUNDS THAT MODULATE ANTI-TUMOR IMMUNITY AND METHODS OF DOING THE SAME | HEITMEIER, KENDALL NICOLE | 24d overdue |
| 18007308 | THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE | CORNET, JEAN P | 9d overdue |
| 16340738 | METHOD AND APPARATUS FOR IMPROVED DETERMINATION OF NODE INFLUENCE IN A NETWORK | LIU, GUOZHEN | 9d overdue |
| 19094455 | SYSTEMS AND METHODS FOR AUTOMATED BUILDING CODE CONFORMANCE | SITTNER, MATTHEW T | 5d overdue |
| 18013954 | EXERGY-BASED LIFE CYCLE ASSESSMENT OF BUILDINGS | YESILDAG, MEHMET | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17772266 | GENE THERAPY VECTORS | PENNINGTON, KATIE LEIGH | 51d overdue |
| 17275399 | SLOW-CYCLING CELL-RNA BASED NANOPARTICLE VACCINE TO TREAT CANCER | PENNINGTON, KATIE LEIGH | 17d overdue |
| 18007308 | THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE | CORNET, JEAN P | 9d overdue |
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | KONOPKA, CATHERINE ANNE | 20d |
| 17762543 | VACCINE THERAPY FOR RAN PROTEIN DISEASES | WANG, CHANG YU | 35d |
| 18840617 | Compositions and Methods for Suppression of Flowering in Sugarcane and Energycane | JOHNSON, EMILY KATHARINE | 39d |
| 18598468 | IL-1RA CDNAS | ROBINSON, HOPE A | 75d |
| 19682032 | COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1634 | 6 |
| 1652 | 5 |
| 1635 | 5 |
| 1662 | 4 |
| 1643 | 3 |
| 1628 | 3 |
| 1633 | 3 |
| 1637 | 3 |
| 1658 | 3 |
| 1675 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19682032 | COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF | PUTTLITZ, KARL J | 1646 | §103§112 | Non-Final OA | — | Pending | May 19, 2026 |
| 19549567 | CHEST AND ABDOMEN RESTRICTION DEVICE | MILO, MICHAEL | 3786 | §102§103 | Non-Final OA | — | Pending | Feb 25, 2026 |
| 19025063 | SYSTEM AND METHOD FOR PERFORMING MULTICAST AUTHENTICATION IN NETWORK-ON-CHIP SYSTEMS | MCFARLAND-BARNES, KELAH JANAE | 2431 | §103 | Final Rejection | — | Pending | Jan 16, 2025 |
| 18874975 | THIAZOLIDINEDIONES FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | INAM, SAHAR | 1622 | §102§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18870030 | CELL-FREE DNA CONCENTRATION IN HYPOTHERMIC MACHINE PERFUSATE AS A RAPID MARKER FOR KIDNEY GRAFT QUALITY | TIWARI, VYOMA SHUBHAM | 1634 | §103§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18865936 | APPARATUS AND METHOD FOR DETERMINING STIMULATION PARAMETERS FOR DEEP BRAIN STIMULATION (DBS) | WEHRHEIM, LINDSEY GAIL | 3799 | §102 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18912748 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18904760 | UTILIZATION OF STATIC STRUCTURES IN ADVANCED BUILDING ENVELOPE SYSTEMS TO IMPROVE LIGHTING, THERMAL, ACOUSTIC, AND STORM PROTECTION PERFORMANCE | CHOI, ALICIA M | — | §102§103§112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18884901 | SITE-SPECIFIC INTEGRATING RECOMBINANT AAV VECTORS FOR GENE THERAPY AND IMPROVED PRODUCTION METHODS | JOHNSON, ALLISON MARIE | 1638 | §102§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18842118 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | SHAMEEM, GOLAM M | — | §112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18841754 | RAN PROTEINS IN SPORADIC AMYOTROPHIC LATERAL SCLEROSIS | MEAH, MOHAMMAD Y | 1652 | §103§112 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18840617 | Compositions and Methods for Suppression of Flowering in Sugarcane and Energycane | JOHNSON, EMILY KATHARINE | 1662 | §103§112 | Final Rejection | 39d | Pending | Aug 22, 2024 |
| 18835859 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | WELLS, LAUREN QUINLAN | 1622 | §102§103§112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18835643 | METHOD, APPARATUS, AND SYSTEM FOR MANUAL SURGICAL DISSECTION | BLAISE, BRADFORD CHRISTOPHER | 3794 | — | Final Rejection | — | Pending | Aug 02, 2024 |
| 18720572 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | CORNET, JEAN P | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18734296 | CONTEXT-SENSITIVE FLOW INTERRUPTER AND DRAINAGE OUTFLOW OPTIMIZATION SYSTEM | ZIMBOUSKI, ARIANA | 3781 | — | Final Rejection | — | Pending | Jun 05, 2024 |
| 18706881 | IMPROVED GENETIC TRANSFORMATION BY IMPROVING DE-NOVO SHOOT REGENERATION IN ADULT PLANTS AND DURING IN-VITRO TISSUE CULTURE | JOHNSON, EMILY KATHARINE | 1662 | §102§103§112 | Final Rejection | — | Pending | May 02, 2024 |
| 18706176 | AAV-MEDIATED THERAPIES FOR VISION LOSS ASSOCIATED WITH FRIEDREICH’S ATAXIA | LARA, CAROLINE MONSERRAT | 1633 | §103DP | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18704712 | SMALL MOLECULE DEGRADATION METHODS FOR TREATING ALS/FTD | ROCHELLE, CIERRA MARIE | 1627 | §112DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18696085 | GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY | RAHMAN, MASUDUR | 1633 | §102§103 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18693658 | BIOMARKER REFLECTANCE SIGNATURES FOR DISEASE DETECTION AND CLASSIFICATION | KORANG-BEHESHTI, YOSSEF | 2857 | §101§102§103 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18692438 | AAVRH74 PARTICLES FOR GENE THERAPY OF MUSCLE DISEASE | RYAN, DOUGLAS CHARLES | 1635 | §101§102§103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18692493 | AAV PARTICLES WITH MODIFIED INVERTED TERMINAL REPEATS FOR ENHANCED GENE EXPRESSION IN MUSCLE | SMALL, KATHERINE R | 1633 | §102§103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18598468 | IL-1RA CDNAS | ROBINSON, HOPE A | 1652 | §103§112 | Final Rejection | 75d | Pending | Mar 07, 2024 |
| 18595698 | DYNAMIC REFINEMENT OF HARDWARE ASSERTION CHECKERS | LIN, ARIC | 2851 | §102§103 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18686633 | RADIATION COMPATIBLE EXPANDER FOR BREAST RECONSTRUCTION | FLORES, ADRIAN | 3774 | §102§103 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18290734 | CONTROLLING PRO-INFLAMMATORY MACROPHAGE PHENOTYPE THROUGH BIOFUNCTIONAL HYDROGEL DESIGN | BEANE, RANDALL L | 1654 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18537160 | SYSTEMS AND METHODS FOR PROVIDING DISTRIBUTED BATTERIES IN INTEGRATED CIRCUITS | DINH, PAUL | — | §102 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18288301 | SYNTHETIC AAV VECTORS FOR REPEATED DELIVERY OF THERAPEUTIC GENES | KNIGHT, TERESA E | 1634 | §102 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18287690 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | BARSKY, JARED | 1628 | §102§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287711 | AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287368 | AGENTS FOR MANUFACTURE OF CO-ASSEMBLING PEPTIDES | JAUHARI, SACHI | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18286450 | EXOSOME GENE THERAPY FOR TREATING INNER EAR DISEASE | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18286453 | COMPOSITIONS AND METHODS FOR TREATING OBESITY | ALDARONDO, DASIA ALI | 1658 | §103§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18286046 | ENZYMATIC SYNTHESIS OF MYCOSPORINE-LIKE AMINO ACIDS | RAMIREZ, DELIA M | 1652 | §112Other | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18552486 | PREDICTION OF POST-OPERATIVE PAIN USING HOSVD | STONE, RACHAEL SOJIN | 3681 | §101§103 | Non-Final OA | 77d overdue | Pending | Sep 26, 2023 |
| 18282503 | CHIMERIC PHAGOCYTIC RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | HUYNH, PHUONG N | 1641 | §103§112 | Final Rejection | — | Pending | Sep 15, 2023 |
| 18236078 | PROTEIN-PEG INTERACTIONS THAT REDIRECT THE THERMAL UNFOLDING PATHWAY OF PEGYLATED HUMAN GALECTIN-3C | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18031505 | SELF-ASSEMBLING URICASE FUSION PEPTIDES | MOEHLMAN, ANDREW TERRY | 1655 | §103§112 | Final Rejection | 41d | Pending | Aug 18, 2023 |
| 18451509 | SPATIO-TEMPORAL INTELLIGENT DIGITAL MEMORY SYSTEMS AND METHODS | COLEMAN, PAUL | 2126 | §103 | Final Rejection | — | Pending | Aug 17, 2023 |
| 18274980 | TREATING DISORDERS ASSOCIATED WITH DYRK1A DYSFUNCTION | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18271769 | SYNERGISTIC MIXTURES COMPRISING PYRETHRUM FOR ARTHROPOD TOXICITY AND REPELLENCY | MELLER, MICHAEL V | 1655 | §101§102§103 | Final Rejection | — | Pending | Jul 11, 2023 |
| 18271584 | ANTICANCER COMPOUNDS AND USES THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §112 | Final Rejection | — | Pending | Jul 10, 2023 |
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | KONOPKA, CATHERINE ANNE | 1635 | §103§112 | Final Rejection | 20d | Pending | Jun 14, 2023 |
| 18257237 | DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19 | COFFA, SERGIO | 1658 | §103DP | Final Rejection | 56d | Pending | Jun 13, 2023 |
| 18331891 | DIRECT CONVERSION OF HUMAN MESENCHYMAL STEM CELLS TO HUMAN CARDIOMYOCYTES | KASAYAN, KATRIEL BARCELLANO | 1634 | §112 | Final Rejection | — | Pending | Jun 08, 2023 |
| 18038321 | USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | — | Pending | May 23, 2023 |
| 18037364 | MULTIFUNCTION MICROFLUIDIC OPTRODE | ROANE, AARON F | 3796 | §102 | Non-Final OA | — | Pending | May 17, 2023 |
| 18253010 | Modified Insecticidal Proteins | MEADOWS, CHRISTINA L | 1663 | §112 | Final Rejection | 35d overdue | Pending | May 15, 2023 |
| 18316064 | DISTRIBUTED LEDGER PLATFORM FOR ELECTRONIC VOTING AND/OR POLLING | LEE, CLAY C | 3699 | §101§103 | Final Rejection | 35d overdue | Pending | May 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Florida Research Foundation Inc. has 115 pending office actions as of October 2026, spread across 68 art units and 106 examiners.
Hope A Robinson has the most, with 3 of University of Florida Research Foundation Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
